169 related articles for article (PubMed ID: 38575784)
1. Antibody drug conjugate combats inflammation.
Crunkhorn S
Nat Rev Drug Discov; 2024 May; 23(5):340. PubMed ID: 38575784
[No Abstract] [Full Text] [Related]
2. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
Wolska-Washer A; Robak T
Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
[TBL] [Abstract][Full Text] [Related]
3. The next generation of antibody-drug conjugates comes of age.
Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
[TBL] [Abstract][Full Text] [Related]
4. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
Okeley NM; Alley SC; Senter PD
Hematol Oncol Clin North Am; 2014 Feb; 28(1):13-25. PubMed ID: 24287064
[TBL] [Abstract][Full Text] [Related]
5. [Advances in research on monoclonal antibody agents for cancer therapy].
Zhen Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):9-13. PubMed ID: 12903485
[TBL] [Abstract][Full Text] [Related]
6. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
Jackson D; Stover D
Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
[TBL] [Abstract][Full Text] [Related]
7. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
Damle NK; Frost P
Curr Opin Pharmacol; 2003 Aug; 3(4):386-90. PubMed ID: 12901947
[TBL] [Abstract][Full Text] [Related]
8. [Immunogenicity of therapeutic antibodies].
Stas P; Lasters I
Med Sci (Paris); 2009 Dec; 25(12):1070-7. PubMed ID: 20035681
[TBL] [Abstract][Full Text] [Related]
9. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
Dinarello CA; Simon A; van der Meer JW
Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
11. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
Golay J; Introna M
Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
[TBL] [Abstract][Full Text] [Related]
13. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
Sibilia J
Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
[TBL] [Abstract][Full Text] [Related]
14. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
Vaklavas C; Forero A
BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
[TBL] [Abstract][Full Text] [Related]
15. Biological disease modifying anti-rheumatic drugs.
Cranwell-Bruce LA
Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
[No Abstract] [Full Text] [Related]
16. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.
Goldmacher VS; Kovtun YV
Ther Deliv; 2011 Mar; 2(3):397-416. PubMed ID: 22834009
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugate for advanced melanoma?
Sharma SP
Lancet Oncol; 2014 Nov; 15(12):e534. PubMed ID: 25602109
[No Abstract] [Full Text] [Related]
20. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.
AlDeghaither D; Smaglo BG; Weiner LM
J Clin Pharmacol; 2015 Mar; 55 Suppl 3(0 3):S4-20. PubMed ID: 25707963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]